Skip to main content

Ildstad Suzanne's Form 4/A amendment

Amended

Tourmaline Bio, Inc. (TRML) · filed Apr 7, 2023

Accession no.
0001209191-23-023789
Filed
Apr 7, 2023
Trade date
Mar 17, 2023
Filing delay
21 days
Rule 10b5-1 plan
Checked
Original filed
Mar 20, 2023

This filing lists 1 non-derivative transaction. Open-market sales total $21.5K. It was filed 21 days after the trade.

This amendment replaces 0001209191-23-020049 (filed Mar 20, 2023).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ildstad SuzanneCIK 0001845822Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 17, 2023Common StockSSaleDisposed−10,436$2.06F1,F2−$21,498.163,054,124Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This amendment is being filed solely to indicated the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.05 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F4

These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read the full filing on SEC EDGAR (opens in a new tab)